191 related articles for article (PubMed ID: 12921512)
1. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists.
Navari RM; Koeller JM
Ann Pharmacother; 2003 Sep; 37(9):1276-86. PubMed ID: 12921512
[TBL] [Abstract][Full Text] [Related]
2. Single-dose, placebo-controlled, phase I study of oral dolasetron.
Dixon RM; Cramer M; Shah AK; Whitmore J; Benedict CR; Hahne WF
Pharmacotherapy; 1996; 16(2):245-52. PubMed ID: 8820468
[TBL] [Abstract][Full Text] [Related]
3. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer.
Pinarli FG; Elli M; Dagdemir A; Baysal K; Acar S
Pediatr Blood Cancer; 2006 Oct; 47(5):567-71. PubMed ID: 16317736
[TBL] [Abstract][Full Text] [Related]
4. 5-HT3 receptor antagonists for prevention of late acute-onset emesis.
Constenla M
Ann Pharmacother; 2004 Oct; 38(10):1683-91. PubMed ID: 15316106
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H
Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666
[TBL] [Abstract][Full Text] [Related]
6. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
7. Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review.
Tricco AC; Soobiah C; Hui W; Antony J; Struchkov V; Hutton B; Hemmelgarn B; Moher D; Straus SE
BMC Pharmacol Toxicol; 2015 Jan; 16():1. PubMed ID: 25623303
[TBL] [Abstract][Full Text] [Related]
8. Multiple-dose, placebo-controlled, phase I study of oral dolasetron.
Hunt TL; Cramer M; Christy-Bittel J; Shah AK; Meyerson LJ; Benedict CR; Hahne WF
Pharmacotherapy; 1996; 16(2):253-60. PubMed ID: 8820469
[TBL] [Abstract][Full Text] [Related]
9. [Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
Alon E; Biro P
Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 May; 31(4):200-4. PubMed ID: 8704077
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative nausea and vomiting after craniotomy: a meta-analysis.
Neufeld SM; Newburn-Cook CV
J Neurosurg Anesthesiol; 2007 Jan; 19(1):10-7. PubMed ID: 17198095
[TBL] [Abstract][Full Text] [Related]
11. Timing of administration of dolasetron affects dose necessary to prevent postoperative nausea and vomiting.
Korttila KT; Jokinen JD
J Clin Anesth; 2004 Aug; 16(5):364-70. PubMed ID: 15374558
[TBL] [Abstract][Full Text] [Related]
12. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
[TBL] [Abstract][Full Text] [Related]
13. [Anti-5-HT-3: a new group of antiemetics].
Galindo JR
Rev Clin Esp; 1996 Feb; 196(2):119-24. PubMed ID: 8685484
[No Abstract] [Full Text] [Related]
14. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
15. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
Keefe DL
Oncologist; 2002; 7(1):65-72. PubMed ID: 11854548
[TBL] [Abstract][Full Text] [Related]
16. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
Gridelli C
Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers.
Hunt TL; Cramer M; Shah A; Stewart W; Benedict CR; Hahne WF
J Clin Pharmacol; 1995 Jul; 35(7):705-12. PubMed ID: 7560251
[TBL] [Abstract][Full Text] [Related]
18. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers.
Benedict CR; Arbogast R; Martin L; Patton L; Morrill B; Hahne W
J Cardiovasc Pharmacol; 1996 Jul; 28(1):53-9. PubMed ID: 8797136
[TBL] [Abstract][Full Text] [Related]
19. First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
Goldsmith B
Acta Oncol; 2004 Sep; 43 Suppl 15():19-22. PubMed ID: 15370626
[No Abstract] [Full Text] [Related]
20. Effects of granisetron with doxorubicin or epirubicin on ECG intervals.
Jantunen IT; Kataja VV; Muhonen TT; Parviainen T
Cancer Chemother Pharmacol; 1996; 37(5):502-4. PubMed ID: 8599877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
